Cerebral microbleeds and risk of symptomatic hemorrhagic transformation following mechanical thrombectomy for large vessel ischemic stroke.

Cerebral microbleeds MRI Mechanical thrombectomy Prognosis Stroke

Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
14 Feb 2024
Historique:
received: 18 10 2023
accepted: 16 01 2024
revised: 08 01 2024
medline: 15 2 2024
pubmed: 15 2 2024
entrez: 14 2 2024
Statut: aheadofprint

Résumé

In patients with acute ischemic stroke (AIS) treated with endovascular therapy (EVT), the association of pre-existing cerebral small vessel disease (cSVD) with symptomatic intracerebral hemorrhage (sICH) remains controversial. We tested the hypothesis that the presence of cerebral microbleeds (CMBs) and their burden would be associated with sICH after EVT of AIS. We conducted a retrospective study combining cohorts of patients that underwent EVT between January 1st 2015 and January 1st 2020. CMB presence, burden, and other cSVD markers were assessed on a pre-treatment MRI, evaluated independently by two observers. Primary outcome was the occurrence of sICH. 445 patients with pretreatment MRI were included, of which 70 (15.7%) demonstrated CMBs on baseline MRI. sICH occurred in 36 (7.6%) of all patients. Univariate analysis did not demonstrate an association between CMB and the occurrence of sICH (7.5% in CMB+ group vs 8.6% in CMB group, p = 0.805). In multivariable models, CMBs' presence was not significantly associated with increased odds for sICH (-aOR- 1.19; 95% CI [0.43-3.27], p = 0.73). Only ASPECTs (aOR 0.71 per point increase; 95% CI [0.60-0.85], p < 0.001) and collaterals status (aOR 0.22 for adequate versus poor collaterals; 95% CI [0.06-0.93], p 0.019) were independently associated with sICH. CMB presence and burden is not associated with increased occurrence of sICH after EVT. This result incites not to exclude patients with CMBs from EVT. The risk of sICH after EVT in patients with more than10 CMBs will require further investigation. Registration-URL: http://www. gov ; Unique identifier: NCT01062698.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
In patients with acute ischemic stroke (AIS) treated with endovascular therapy (EVT), the association of pre-existing cerebral small vessel disease (cSVD) with symptomatic intracerebral hemorrhage (sICH) remains controversial. We tested the hypothesis that the presence of cerebral microbleeds (CMBs) and their burden would be associated with sICH after EVT of AIS.
METHODS METHODS
We conducted a retrospective study combining cohorts of patients that underwent EVT between January 1st 2015 and January 1st 2020. CMB presence, burden, and other cSVD markers were assessed on a pre-treatment MRI, evaluated independently by two observers. Primary outcome was the occurrence of sICH.
RESULTS RESULTS
445 patients with pretreatment MRI were included, of which 70 (15.7%) demonstrated CMBs on baseline MRI. sICH occurred in 36 (7.6%) of all patients. Univariate analysis did not demonstrate an association between CMB and the occurrence of sICH (7.5% in CMB+ group vs 8.6% in CMB group, p = 0.805). In multivariable models, CMBs' presence was not significantly associated with increased odds for sICH (-aOR- 1.19; 95% CI [0.43-3.27], p = 0.73). Only ASPECTs (aOR 0.71 per point increase; 95% CI [0.60-0.85], p < 0.001) and collaterals status (aOR 0.22 for adequate versus poor collaterals; 95% CI [0.06-0.93], p 0.019) were independently associated with sICH.
CONCLUSION CONCLUSIONS
CMB presence and burden is not associated with increased occurrence of sICH after EVT. This result incites not to exclude patients with CMBs from EVT. The risk of sICH after EVT in patients with more than10 CMBs will require further investigation.
REGISTRATION BACKGROUND
Registration-URL: http://www.
CLINICALTRIALS RESULTS
gov ; Unique identifier: NCT01062698.

Identifiants

pubmed: 38355868
doi: 10.1007/s00415-024-12205-7
pii: 10.1007/s00415-024-12205-7
doi:

Banques de données

ClinicalTrials.gov
['NCT01062698']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Références

Yaghi S, Willey JZ, Cucchiara B et al (2017) Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 48:e343–e361. https://doi.org/10.1161/STR.0000000000000152
doi: 10.1161/STR.0000000000000152 pubmed: 29097489
Kaesmacher J, Kaesmacher M, Maegerlein C et al (2017) Hemorrhagic transformations after thrombectomy: risk factors and clinical relevance. Cerebrovasc Dis Basel Switz 43:294–304. https://doi.org/10.1159/000460265
doi: 10.1159/000460265
Whiteley WN, Slot KB, Fernandes P et al (2012) Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke 43:2904–2909. https://doi.org/10.1161/STROKEAHA.112.665331
doi: 10.1161/STROKEAHA.112.665331 pubmed: 22996959
Wen L, Zhang S, Wan K et al (2020) Risk factors of haemorrhagic transformation for acute ischaemic stroke in Chinese patients receiving intravenous thrombolysis. Med (Baltim) 99:e18995. https://doi.org/10.1097/MD.0000000000018995
doi: 10.1097/MD.0000000000018995
Goyal M, Menon BK, van Zwam WH et al (2016) Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. The Lancet 387:1723–1731. https://doi.org/10.1016/S0140-6736(16)00163-X
doi: 10.1016/S0140-6736(16)00163-X
Derraz I, Cagnazzo F, Gaillard N et al (2021) Microbleeds, cerebral hemorrhage, and functional outcome after endovascular thrombectomy. Neurology 96:e1724–e1731. https://doi.org/10.1212/WNL.0000000000011566
doi: 10.1212/WNL.0000000000011566 pubmed: 33495380
Shi Z-S, Duckwiler GR, Jahan R et al (2016) Mechanical thrombectomy for acute ischemic stroke with cerebral microbleeds. J Neurointerventional Surg 8:563–567. https://doi.org/10.1136/neurintsurg-2015-011765
doi: 10.1136/neurintsurg-2015-011765
Wu X, Yan J, Ye H et al (2020) Pre-treatment cerebral microbleeds and intracranial hemorrhage in patients with ischemic stroke receiving endovascular therapy: a systematic review and meta-analysis. J Neurol 267:1227–1232. https://doi.org/10.1007/s00415-019-09210-6
doi: 10.1007/s00415-019-09210-6 pubmed: 30689017
Montalvo M, Mistry E, Chang AD et al (2019) Predicting symptomatic intracranial haemorrhage after mechanical thrombectomy: the TAG score. J Neurol Neurosurg Psychiatry 90:1370–1374. https://doi.org/10.1136/jnnp-2019-321184
doi: 10.1136/jnnp-2019-321184 pubmed: 31427365
Zhang X, Xie Y, Wang H et al (2020) Symptomatic intracranial hemorrhage after mechanical thrombectomy in chinese ischemic stroke patients: the ASIAN score. Stroke 51:2690–2696. https://doi.org/10.1161/STROKEAHA.120.030173
doi: 10.1161/STROKEAHA.120.030173 pubmed: 32811387
Yan S, Jin X, Zhang X et al (2015) Extensive cerebral microbleeds predict parenchymal haemorrhage and poor outcome after intravenous thrombolysis. J Neurol Neurosurg Psychiatry 86:1267–1272. https://doi.org/10.1136/jnnp-2014-309857
doi: 10.1136/jnnp-2014-309857 pubmed: 25632155
Charidimou A, Shoamanesh A, Wilson D et al (2015) Cerebral microbleeds and postthrombolysis intracerebral hemorrhage risk Updated meta-analysis. Neurology 85:927–924. https://doi.org/10.1212/WNL.0000000000001923
doi: 10.1212/WNL.0000000000001923 pubmed: 26296519 pmcid: 4567460
Tsivgoulis G, Zand R, Katsanos AH et al (2016) Risk of symptomatic intracerebral hemorrhage after intravenous thrombolysis in patients with acute ischemic stroke and high cerebral microbleed burden: a meta-analysis. JAMA Neurol 73:675–683. https://doi.org/10.1001/jamaneurol.2016.0292
doi: 10.1001/jamaneurol.2016.0292 pubmed: 27088650
Charidimou A, Turc G, Oppenheim C et al (2017) Microbleeds, cerebral hemorrhage, and functional outcome after stroke thrombolysis. Stroke 48:2084–2090. https://doi.org/10.1161/STROKEAHA.116.012992
doi: 10.1161/STROKEAHA.116.012992 pubmed: 28720659
Bracard S, Ducrocq X, Mas JL et al (2016) Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol 15:1138–1147. https://doi.org/10.1016/S1474-4422(16)30177-6
doi: 10.1016/S1474-4422(16)30177-6 pubmed: 27567239
Wardlaw JM, Smith EE, Biessels GJ et al (2013) Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 12:822–838. https://doi.org/10.1016/S1474-4422(13)70124-8
doi: 10.1016/S1474-4422(13)70124-8 pubmed: 23867200 pmcid: 3714437
Staals J, Makin SDJ, Doubal FN et al (2014) Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology 83:1228–1234. https://doi.org/10.1212/WNL.0000000000000837
doi: 10.1212/WNL.0000000000000837 pubmed: 25165388 pmcid: 4180484
Amin Al Olama A, Wason JMS, Tuladhar AM et al (2020) Simple MRI score aids prediction of dementia in cerebral small vessel disease. Neurology 94:e1294–e1302. https://doi.org/10.1212/WNL.0000000000009141
doi: 10.1212/WNL.0000000000009141 pubmed: 32123050 pmcid: 7274929
Liebeskind DS, Tomsick TA, Foster LD et al (2014) Collaterals at angiography and outcomes in the interventional management of stroke (IMS) III trial. Stroke 45:759–764. https://doi.org/10.1161/STROKEAHA.113.004072
doi: 10.1161/STROKEAHA.113.004072 pubmed: 24473178 pmcid: 3977615
Hacke W, Kaste M, Fieschi C et al (1998) Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet Lond Engl 352:1245–1251. https://doi.org/10.1016/s0140-6736(98)08020-9
doi: 10.1016/s0140-6736(98)08020-9
Hacke W, Kaste M, Bluhmki E et al (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359:1317–1329. https://doi.org/10.1056/NEJMoa0804656
doi: 10.1056/NEJMoa0804656 pubmed: 18815396
von Elm E, Altman DG, Egger M et al (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. The Lancet 370:1453–1457. https://doi.org/10.1016/S0140-6736(07)61602-X
doi: 10.1016/S0140-6736(07)61602-X
Choi K-H, Kim J-H, Kang K-W et al (2019) Impact of microbleeds on outcome following recanalization in patients with acute ischemic stroke. Stroke 50:127–134. https://doi.org/10.1161/STROKEAHA.118.023084
doi: 10.1161/STROKEAHA.118.023084 pubmed: 30580721
Diedler J, Ahmed N, Sykora M et al (2010) Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke 41:288–294. https://doi.org/10.1161/STROKEAHA.109.559724
doi: 10.1161/STROKEAHA.109.559724 pubmed: 20056933
Luo S, Zhuang M, Zeng W, Tao J (2016) Intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy: a systematic review and meta-analysis of 19 studies. J Am Heart Assoc 5:e003242. https://doi.org/10.1161/JAHA.116.003242
doi: 10.1161/JAHA.116.003242 pubmed: 27207999 pmcid: 4889195
Karaszewski B, Houlden H, Smith EE et al (2015) What causes intracerebral bleeding after thrombolysis for acute ischaemic stroke? Recent insights into mechanisms and potential biomarkers. J Neurol Neurosurg Psychiatry 86:1127–1136. https://doi.org/10.1136/jnnp-2014-309705
doi: 10.1136/jnnp-2014-309705 pubmed: 25814492
De Guio F, Jouvent E, Biessels GJ et al (2016) Reproducibility and variability of quantitative magnetic resonance imaging markers in cerebral small vessel disease. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 36:1319–1337. https://doi.org/10.1177/0271678X16647396
doi: 10.1177/0271678X16647396

Auteurs

Rémi Agbonon (R)

Neuroradiology Department, GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France.
Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, IMA-BRAIN INSERM U1266, Université de Paris, Paris, France.

Géraud Forestier (G)

Neuroradiology Department, GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France. geraud.forestier@chu-limoges.fr.
Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, IMA-BRAIN INSERM U1266, Université de Paris, Paris, France. geraud.forestier@chu-limoges.fr.
Neuroradiology Department, Limoges University Hospital, 2 avenue Martin Luther-King, 87042, Limoges, France. geraud.forestier@chu-limoges.fr.

Nicolas Bricout (N)

Neuroradiology Department, Univ. Lille, Inserm, CHU Lille, U1172-LilNCog (JPARC)-Lille Neurosciences & Cognition, 59000, Lille, France.

Wagih Benhassen (W)

Neuroradiology Department, GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France.
Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, IMA-BRAIN INSERM U1266, Université de Paris, Paris, France.

Guillaume Turc (G)

Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, IMA-BRAIN INSERM U1266, Université de Paris, Paris, France.
Neurology Department, GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France.

Martin Bretzner (M)

Neuroradiology Department, Univ. Lille, Inserm, CHU Lille, U1172-LilNCog (JPARC)-Lille Neurosciences & Cognition, 59000, Lille, France.

Marco Pasi (M)

Univ. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, 59000, Lille, France.

Joseph Benzakoun (J)

Neuroradiology Department, GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France.
Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, IMA-BRAIN INSERM U1266, Université de Paris, Paris, France.

Pierre Seners (P)

Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, IMA-BRAIN INSERM U1266, Université de Paris, Paris, France.
Neurology Department, GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France.

Imad Derraz (I)

Department of Neuroradiology, Hôpital Gui de Chauliac, Montpellier University Medical Center, Montpellier, France.

Laurence Legrand (L)

Neuroradiology Department, GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France.
Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, IMA-BRAIN INSERM U1266, Université de Paris, Paris, France.

Denis Trystram (D)

Neuroradiology Department, GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France.
Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, IMA-BRAIN INSERM U1266, Université de Paris, Paris, France.

Christine Rodriguez-Regent (C)

Neuroradiology Department, GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France.
Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, IMA-BRAIN INSERM U1266, Université de Paris, Paris, France.

Andreas Charidimou (A)

Department of Neurology, J. Philip Kistler Stroke Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Natalia S Rost (NS)

Department of Neurology, J. Philip Kistler Stroke Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Serge Bracard (S)

Neuroradiology Department, Lorraine University, INSERM U1254 CHRU Nancy, Nancy, France.

Charlotte Cordonnier (C)

Univ. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, 59000, Lille, France.

Omer F Eker (OF)

Department of Neuroradiology of Pierre Wertheimer Hospital, Hospices Civils de Lyon, Lyon, France.

Catherine Oppenheim (C)

Neuroradiology Department, GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France.
Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, IMA-BRAIN INSERM U1266, Université de Paris, Paris, France.

Olivier Naggara (O)

Neuroradiology Department, GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France.
Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, IMA-BRAIN INSERM U1266, Université de Paris, Paris, France.

Hilde Henon (H)

Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, IMA-BRAIN INSERM U1266, Université de Paris, Paris, France.
Neurology Department, GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France.

Grégoire Boulouis (G)

Neuroradiology Department, GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France.
Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, INSERM, IMA-BRAIN INSERM U1266, Université de Paris, Paris, France.
Neuroradiology Department, CHU de Tours, Centre Val de Loire Region, Tours, France.

Classifications MeSH